BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Novartis’ Scemblix Shines at ASH While Sandoz Rumors Swirl

  Novartis is going full steam ahead with its cancer development efforts, recently posting positive results from two ongoing trials for lymphoma and leukemia.

  December 13, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Highlights from ASH: GBT, Jazz, Regeneron and More

  The following features are highlights from the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in-person in Atlanta, GA, and virtually from December 11 to 14.

  December 13, 2021

   · 

  4 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Pfizer Augments Inflammation and Immunology Business with $6.7 Billion Buy

  Arena Pharmaceuticals’ share price nearly doubled in premarket trading after Pfizer announced it was acquiring the company and its diverse portfolio of developmental and clinical assets.

  December 13, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Pharm Country

  Omicron Continues to Cause Confusion about Vaccine Response and Origins

  A study out of the University of Oxford found that two shots of the Pfizer-BioNTech vaccine or the AstraZeneca-Oxford vaccine were not as effective at against Omicron as they were against previous variants.

  December 13, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Halberd’s Laser Tech Demonstrates Potential for Treating Alzheimer’s and other CNS Diseases

  Halberd announced that preliminary testing of its extracorporeal laser irradiation methodologies completely eradicated Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF).

  December 13, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  BMS and Kite Unveil CAR-T Successes in Lymphoma

  At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.

  December 13, 2021

   · 

  5 min read

   · 

  Alex Keown
• 

  Drug Development

  Biomarker Data Spurs Possible Comeback of BrainStorm for Amyotrophic Lateral Sclerosis

  BrainStorm Cell Therapeutics is making a strong comeback after the FDA was a little impressed with Phase III results of amyotrophic lateral sclerosis treatment.

  December 13, 2021

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Deals

  Now Trading in Shanghai, BeiGene Unveils Promising Phase III Results

  BeiGene raised $3.3 billion on Shanghai’s STAR market, making it the first company to trade its shares in Shanghai, Hong Kong, and New York.

  December 13, 2021

   · 

  2 min read

   · 

  Alvin Clavines
• 

  Drug Development

  Takeda Puts the Spotlight on Hemophilia Therapies at ASH

  Takeda will present nine abstracts at the annual ASH meeting, including data for its hemophilia program, as well as announcing a new sickle cell disease program.

  December 13, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Orca Bio’s Blood Cancer Therapy Orca-T Has Strong Showing at ASH

  Orca-T demonstrated significantly higher graft-versus-host disease-free, relapse-free survival (GRFS) rates compared to patients who received standard of care.

  December 13, 2021

   · 

  2 min read

   · 

  Sreetama Dutt